Table 1.
Baseline demographic and clinical characteristics of 191 patients who underwent initial thermal ablation for colorectal liver metastasis (CLM) and were included in this study per initial session.
| Characteristic | Value |
|---|---|
| Age, median (IQR), yr | 56.7 (48.6–66.6) |
| Male sex, no. (%) | 121 (63.4) |
| Rectal primary tumour, no. (%) | 39 (20.4) |
| Right-sided primary tumour, no. (%) | 45.0 (23.6%) |
| Node-positive primary tumour, no. (%) | 114 (59.7) |
| Liver metastasis, no. (%) | |
| Metachronous | 86 (45.0) |
| Synchronous | 102 (53.4) |
| N/A | 3 (1.6) |
| Prior hepatic resection for CLM, no. (%) | 117 (61.3%) |
| Extrahepatic metastasis, no. (%) | 111 (58.1) |
| Pre-ablation chemotherapy, no (%) | 142.0 (74.3%) |
| Fluorouracil-based regimen | 127 (66.5%) |
| Oxaliplatin | 74 (38.7%) |
| Irinotecan | 70 (36.6%) |
| Use of Bevacizumab | 90 (47.1%) |
| Lines of pre-ablation chemotherapy | |
| 0 | 49 (25.7%) |
| 1 | 83 (43.5%) |
| 2 | 54 (28.3%) |
| 3 | 5 (2.6%) |
| Number of ablated CLMs, median (IQR) | 1 (1–2) |
| Diameter of largest ablated CLM, median (IQR), cm | 1.4 (1.0–2.0) |
N/A not available, IQR interquartile range.